Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).
SkinAge
2 other identifiers
interventional
58
1 country
1
Brief Summary
Epidemiological data show that the incidence of carcinoma, the most common cancer, is strongly linked to the age. Non Melanoma Skin Carcinomas (NMSCs) (the most frequent cancers in the elderly population) derive from keratinocytes of the basal layer of the epidermis, from differentiated keratinocytes of the more superficial layers or from stem cells of hair follicles. Unlike NMSCs, soft-tissue sarcomas, including those deriving from dermal fibroblasts, are very rare (less than 1% of all cancers). Our overall purpose is to decipher the molecular pathways activated during the aging of these tissues that may explain why they have a so different propensity to undergo a malignant transformation. Given that senescent cells accumulate in the dermis and epidermis with age, we will constitute two groups : "young skin" that we arbitrarily limit to the range ≥ 18 and ≤ 40 and "aged skin" ≥ 55. Thus the main objective of our study is to search within 2 age groups (≥ 18 and ≤ 40 years and ≥ 55 years) the expression of senescence markers on healthy skin tissue.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 7, 2014
CompletedFirst Submitted
Initial submission to the registry
September 17, 2015
CompletedFirst Posted
Study publicly available on registry
September 18, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 16, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2020
CompletedMarch 18, 2026
March 1, 2026
4.5 years
September 17, 2015
March 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Expression of senescence markers in healthy skin tissues collected for the two age groups.
Baseline
Secondary Outcomes (3)
Research of emerging cells in the skin tissue of the subjects of the two age groups via the expression of the Protease-Activated Receptor-1 (PAR-1).
Baseline
Presence of different types of DNA damage (single and double strand breaks) in the keratinocytes and fibroblasts of the skin tissues of the two age groups.
Baseline
Morbidity
Baseline
Study Arms (1)
Collection of healthy skin tissue
EXPERIMENTALCollection of healthy skin tissue
Interventions
Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
Eligibility Criteria
You may qualify if:
- Patient with an operable sarcoma
- Requiring a surgical operation under general anesthesia at the Oscar Lambret Centre
- Age ≥ 18 ans, belonging to one of the two following age groups : \[ ≥ 18 and ≤ 40 years\] and \[ ≥ 55 years\]
- Patient having a social security scheme
- Patient having signed an informed consent form for the study
You may not qualify if:
- Patient aged under 18 or between 41 and 54
- Location of the tumor on the face, neck or neckline
- Patient with a skin tumor
- Tumor-induced cutaneous fistula making suspect a tumor invasion of the skin
- Patient with a chronic skin disease
- Collection in an area already treated by surgery, radiotherapy or brachytherapy
- Pregnant or breastfeeding women
- Patient under guardianship or tutorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centre Oscar Lambretlead
- Institut de Biologie de Lillecollaborator
Study Sites (1)
Centre Oscar Lambret
Lille, 59020, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Nicolas PENEL, MD
Centre Oscar Lambret
- STUDY DIRECTOR
Olivier PLUQUET
Institut de Biologie de Lille
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 17, 2015
First Posted
September 18, 2015
Study Start
October 7, 2014
Primary Completion
April 16, 2019
Study Completion
April 1, 2020
Last Updated
March 18, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share